LH Laboratory Corp of America
- 200.250
- 0.0000.00%
Laboratory Corp of America News
Laboratory Corp of America(LH.US) Director Sells US$101.06K in Common Stock
$Laboratory Corp of America(LH.US)$ Director ANDERSON KERRII B sold 500 shares of common stock on Apr 30, May 2, 2024 at an average price of $202.1166 for a total value of $101.06K.Source: Announcemen
Insider Sale at Laboratory Corp of America Holdings (LH)
Laboratory Corp of America(LH.US) Officer Sells US$498.36K in Common Stock
$Laboratory Corp of America(LH.US)$ Officer Wilkinson Peter J sold 2,439 shares of common stock on Apr 29, 2024 at an average price of $204.329 for a total value of $498.36K.Source: Announcement What
Decoding Laboratory Corp of America Holdings (LH): A Strategic SWOT Insight
Express News | NYSE Order Imbalance 75250.0 Shares on Sell Side
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $255 From $244
Laboratory Corp of America Holdings (LH) has an average rating of outperform and price targets ranging from $210 to $262, according to analysts polled by Capital IQ.
Laboratory Corporation of America Holdings (NYSE:LH) Is Due To Pay A Dividend Of $0.72
Quest Diagnostics, LabCorp Climb Following FDA Testing Oversight Rule
Laboratory Corporation of America on Pace for Largest Percent Increase Since November 2022 -- Data Talk
Laboratory Corporation of America Holdings (LH) is currently at $206.91, up $8.51 or 4.29% --On pace for largest percent increase since Nov. 10, 2022, when it rose 5.44% --Currently up two consecuti
Express News | Labcorp Shares Are Trading Higher After the Company Announced That the FDA Approved Its NABCyte Anti-AAVRh74var HB-FE Assay, a Companion Diagnostic, to Determine Patient Eligibility for Treatment With BEQVEZ
Express News | FDA Approves Labcorp's NAbCyte Anti-AAVRh74var HB-FE, Companion Diagnostic To Determine Patient Eligibility For Treatment With Beqvez (Fidanacogene Elaparvovec-dzkt), Pfizer's Recently FDA-Approved Hemophilia B Gene Therapy
Express News | Labcorp Receives FDA Approval for First Companion Diagnostic for Use With Pfizer's Newly Approved Gene Therapy to Treat Patients With Hemophilia B
Analyst Ratings For Laboratory Corp
In the latest quarter, 5 analysts provided ratings for Laboratory Corp (NYSE:LH), showcasing a mix of bullish and bearish perspectives.The table below offers a condensed view of their recent ratings,
Laboratory Corp. Is Maintained at Outperform by Baird
Laboratory Corp. Is Maintained at Outperform by Baird
Express News | Baird Maintains Outperform on Laboratory Corp, Lowers Price Target to $244
Laboratory Corp Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/26/2024 22% Baird $255 → $244 Maintains Outperform 03/25/2024 — Argus Research Upgrades Hold → Buy 02/
Express News | Labcorp : Barclays Cuts Target Price to $213 From $234
Express News | Labcorp : Truist Securities Cuts Target Price to $255 From $270
Earnings Call Summary | Laboratory Corp of America(LH.US) Q1 2024 Earnings Conference
The following is a summary of the Laboratory Corporation of America Holdings (LH) Q1 2024 Earnings Call Transcript:Financial Performance:Labcorp's Q1 revenue reached $3.2 billion, a 5% increase from Q
Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
Thursday, Labcorp (NYSE:LH) reported first-quarter sales increased 4.6% to $3.18 billion, beating the consensus of $3.12 billion. Base Business grew 6.7%.The increase was due to organic revenue of 2.3
Analysis
Price Target
No Data
